Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections.

Gennaro De PascaleLucia LisiGabriella Maria Pia CiottiMaria Sole VallecocciaSalvatore Lucio CutuliLaura CascaranoCamilla GelorminiGiuseppe BelloLuca MontiniSimone CarelliValentina Di GravioMario TumbarelloMaurizio SanguinettiPierluigi NavarraMassimo Antonelli

Published in: Annals of intensive care (2020)

The use of HD TGC is associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria (MIC < 0.5 mcg/mL). Even higher dosages and combination strategies may be suggested in presence of difficult to treat pathogens, especially in case of SSTI and IAI.

Keyphrases

high dose
early onset
pulmonary hypertension
antimicrobial resistance
gram negative
combination therapy
drug resistant
pseudomonas aeruginosa
cystic fibrosis